Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 62-72

  Brantley, Eileen ^a,d   Antony, Smitha ^b   Kohlhagen, Glenda ^b   Meng, LingHua ^b   Agama, Keli ^b   Stinson, Sherman F ^a   Sausville, Edward A ^c   Pommier, Yves ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

5F 203; Breast cancer; DNA damage; DNA protein cross links; Single strand breaks

Indexed keywords

2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; 2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; CYTOCHROME P450 1A1; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); MESSENGER RNA; NSC 703786; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL STRAIN MCF 7; CONTROLLED STUDY; COVALENT BOND; CROSS LINKING; DNA CLEAVAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; ELUTION; ENZYME INHIBITION; EXCISION REPAIR; GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; XPD GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; HUMANS; THIAZOLES;

EID: 33645999638     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0127-z     Document Type: Article

References (39)

1. Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT, Boyd MR (1994) Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 37:2185-2189
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601
3. Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, Ishikawa H, Saya H (2004) Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9:131-142
4. Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y (1991) Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51:6280-6285
5. Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 10:1663-1682
6. Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MF, Sausville EA, Stinson SF (2004) Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 32:1392-1401
7. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF (2000) Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60:5196-5203
8. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899-4902
9. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C (2002) Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 97:439-445
10. Gibson NW, Hartley JA, Strong JM, Kohn KW (1986) 2-Chloroethyl (methylsulfonyl)methanesulfonate (NSC-338947), a more selective DNA alkylating agent than the chloroethylnitrosoureas. Cancer Res 46:553-557
11. Hose CD, Hollingshead M, Sausville EA, Monks A (2003) Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2:1265-1272
12. Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MF (2001) Antitumor benzothiazoles 14 Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44:1446-1455
13. Jensen PB, Sorensen BS, Demant EJ, Sehested M, Jensen PS, Vindelov L, Hansen HH (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50:3311-3316
14. Johnson DE, Ochieng J, Evans SL (1996) Phenylacetic acid halides inhibit estrogen receptor (ER)-positive MCF-7 cells, but not ER-negative human breast cancer cells or normal breast epithelial cells. Anticancer Drugs 7:288-292
15. Kashiyama E, Hutchinson I, Chua MS, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, Stevens MF (1999) Antitumor benzothiazoles 8 synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. J Med Chem 42:4172-4184
16. Khan QA, Kohlhagen G, Marshall R, Austin CA, Kalena GP, Kroth H, Sayer JM, Jerina DM, Pommier Y (2003) Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer aaents. Proc Natl Acad Sci USA 100:12498-12503
17. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143-153
18. Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG (2003) Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 88:470-477
19. Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MFG, Bradshaw TD (2004) In vitro, in vivo and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 3:1565-1575
20. Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MF, Bradshaw TD, Sausville EA (2002) Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 61:13-19
21. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA (2004) Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3:715-725
22. Meng LH, Kohlhagen G, Liao Zy, Antony S, Sausville E, Pommier Y (2005) DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65:5337-5343
23. Monks A, Harris E, Hose C, Connelly J, Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766-772
24. O'Brien SE, Browne HL, Bradshaw TD, Westwell AD, Stevens MF, Laughton CA (2003) Antitumor benzothiazoles Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A1. Org Biomol Chem 1:493-497
25. Pobst LJ, Ames MM (2005) CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother Pharmacol 11:1-8
26. Pommier Y, Goldwasser F, Strumberg D (2001) (eds) Topoisomerase II inhibitors: epipodophyllotoxins, acridines, ellipticines, and bisdioxopiperazines. Lippincott Williams & Wilkins, Philadelphia
27. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861-8865
28. Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW (2005) Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.Curr Pharm Des 11:2855-2872
29. Reardon JT, Sancar A (2002) Molecular anatomy of the human excision nuclease assembled at sites of DNA damage. Mol Cell Biol 22:5938-5945
30. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA (1999) Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol 57:1283-1295
31. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y (1997) Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57:4029-4035
32. Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y (1993) Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 45:2449-2456
33. Strumberg D, Pommier Y, Paull K, Jayaraman M, Nagafuji P, Cushman M (1999) Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem 42:446-457
34. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y (2001) Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase 1 expression. Clin Cancer Res 7:185-191
35. Trapani V, Patel V, Leong CO, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MF, Sausville EA, Loaiza-Perez AI (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 88:599-605
36. Urasaki Y, Takebayashi Y, Pommier Y (2000) Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res 60:6577-6580
37. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440
38. Wu X, Fan W, Xu S, Zhou Y (2003) Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 9:5874-5879
39. Zhelkovsky AM, Moore CL (1994) Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector. Protein Expr Purif 5:364-370